Management ChangeMay 8, 2026, 09:26 AM
Tango Therapeutics Finalizes CFO Daniella Beckman's Separation
AI Summary
Tango Therapeutics formalized the separation of its former Chief Financial Officer, Daniella Beckman, through a Separation Agreement and Release dated May 7, 2026. Ms. Beckman ceased her role on April 15, 2026. Under the agreement, she will receive 12 months of severance pay, 12 months of COBRA premium reimbursement, and accelerated vesting of certain equity awards, in exchange for a general release.
Key Highlights
- Daniella Beckman's separation as CFO formalized via agreement on May 7, 2026.
- Ms. Beckman ceased serving as CFO effective April 15, 2026.
- Will receive 12 months of severance pay at current base salary.
- Eligible for up to 12 months of COBRA premium reimbursement.
- Equity awards to vest as if she remained for an additional 24 months.
- Vested stock option exercise period extended through August 31, 2026.
- Ms. Beckman executed a general release in favor of the Company.
Price Impact
More from TNGX